Protagonist Therapeutics
PTGX
PTGX
166 hedge funds and large institutions have $1.57B invested in Protagonist Therapeutics in 2023 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 59 increasing their positions, 48 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
166
Holders Change
+30
Holders Change %
+22.06%
% of All Funds
2.62%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.08%
New
44
Increased
59
Reduced
48
Closed
14
Calls
$49.7M
Puts
$22.8M
Net Calls
+$26.8M
Net Calls Change
-$2.27M
Top Buyers
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
$125M |
| 2 |
CAC
Cowen and Company
New York
|
$45.8M |
| 3 |
State Street
Boston,
Massachusetts
|
$98.1M |
| 4 |
RI
RTW Investments
New York
|
$150M |
| 5 |
Holocene Advisors
New York
|
$22.2M |
Top Sellers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
$35.7M |
| 2 |
Marshall Wace
London,
United Kingdom
|
$4.54M |
| 3 |
Morgan Stanley
New York
|
$16M |
| 4 |
Millennium Management
New York
|
$9.72M |
| 5 |
Citadel Advisors
Miami,
Florida
|
$15.2M |
